Suppr超能文献

心脏手术中的血小板输注:系统评价和荟萃分析。

Platelet Transfusion in Cardiac Surgery: A Systematic Review and Meta-Analysis.

机构信息

Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

出版信息

Ann Thorac Surg. 2021 Feb;111(2):607-614. doi: 10.1016/j.athoracsur.2020.04.139. Epub 2020 Jun 23.

Abstract

BACKGROUND

Blood transfusion is a well-established independent risk factor for mortality in patients undergoing cardiac surgery but the impact of platelet transfusion is less clear. We performed a systematic review and meta-analysis of observational studies comparing outcomes of patients who received platelet transfusion after cardiac surgery.

METHODS

We searched MEDLINE and EMBASE databases to January 2019 for studies comparing perioperative outcomes in patients undergoing cardiac surgery with and without platelet transfusion.

RESULTS

There were nine observational studies reporting 101,511 patients: 12% with and 88% without platelet transfusion. In unmatched/unadjusted studies, patients who received platelet transfusion were older, with greater incidence of renal, peripheral, and cerebrovascular disease, myocardial infarction, left ventricular dysfunction, and anemia. They were more likely to have nonelective, combined surgery; preoperative hemodynamic instability and endocarditis; and more likely to be receiving clopidogrel preoperatively. Perioperative complications were significantly increased without adjusting for these baseline differences. After pooling only matched/adjusted data, differences were not found between patients who did receive platelets and patients who did not in operative mortality (risk ratio [RR] 1.26; 95% confidence interval [CI], 0.69 to 2.32, P = .46, five studies), stroke (RR 0.94; 95% CI, 0.62 to 1.45; P = .79; five studies), myocardial infarction (RR 1.29; 95% CI, 0.95 to 1.77; P = .11; three studies), reoperation for bleeding (RR 1.20; 95% CI, 0.46 to 3.18; P = .71; three studies), infection (RR 1.02; 95% CI, 0.86 to 1.20; P = .85; six studies); and perioperative dialysis (RR 0.91; 95% CI, 0.63 to 1.32; P = .62; three studies).

CONCLUSIONS

After accounting for baseline differences, platelet transfusion was not linked with perioperative complications in cardiac surgery patients. Given the small number of observational studies, these findings should be considered hypothesis generating.

摘要

背景

输血是心脏手术患者死亡的一个明确的独立危险因素,但血小板输血的影响尚不清楚。我们对比较心脏手术后接受血小板输血和未接受血小板输血患者结局的观察性研究进行了系统回顾和荟萃分析。

方法

我们检索了 MEDLINE 和 EMBASE 数据库,以获取截至 2019 年 1 月比较心脏手术患者围术期结局的研究。

结果

有 9 项观察性研究报告了 101511 例患者:12%接受了血小板输血,88%未接受血小板输血。在未匹配/未调整的研究中,接受血小板输血的患者年龄较大,合并肾功能不全、周围血管疾病、脑血管疾病、心肌梗死、左心室功能障碍和贫血的发生率较高。他们更有可能进行非择期、联合手术;术前血流动力学不稳定和心内膜炎;并且更有可能在术前接受氯吡格雷治疗。在未调整这些基线差异的情况下,围手术期并发症显著增加。仅汇总匹配/调整数据后,与未接受血小板输血的患者相比,接受血小板输血的患者在手术死亡率(风险比 [RR] 1.26;95%置信区间 [CI],0.69 至 2.32,P=0.46,5 项研究)、卒(RR 0.94;95% CI,0.62 至 1.45;P=0.79;5 项研究)、心肌梗死(RR 1.29;95% CI,0.95 至 1.77;P=0.11;3 项研究)、因出血再次手术(RR 1.20;95% CI,0.46 至 3.18;P=0.71;3 项研究)、感染(RR 1.02;95% CI,0.86 至 1.20;P=0.85;6 项研究)和围术期透析(RR 0.91;95% CI,0.63 至 1.32;P=0.62;3 项研究)方面无差异。

结论

在考虑到基线差异后,血小板输血与心脏手术患者的围手术期并发症无关。鉴于观察性研究的数量较少,这些发现应被视为假设生成。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验